ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALSGlobeNewsWire • 04/09/24
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent HighlightsGlobeNewsWire • 04/01/24
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein VaccineGlobeNewsWire • 01/22/24
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's DiseaseGlobeNewsWire • 11/20/23
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent HighlightsGlobeNewsWire • 11/14/23
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/06/23
ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent HighlightsGlobeNewsWire • 08/14/23
ProMIS Showcases Preclinical Data at the Alzheimer's Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer's PipelineGlobeNewsWire • 07/17/23
ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions ApprovedGlobeNewsWire • 06/30/23
CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern TimeGlobeNewsWire • 06/29/23
ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent HighlightsGlobeNewsWire • 05/15/23
ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer's DiseaseGlobeNewsWire • 05/08/23
Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer's DiseaseGlobeNewsWire • 04/25/23
ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer's Disease and ALS at American Academy of Neurology Annual MeetingGlobeNewsWire • 04/24/23